News
Feed
Events
Feed
News
+ Events
Feed

CureVac

  • ISIN NL0015436031
  • Country Deutschland

Latest News

11 July 2024

13:00 Corporate

CureVac

Corporate

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

3 July 2024

08:12 Corporate

CureVac

Corporate

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

08:09 Corporate

CureVac

Corporate

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

24 June 2024

22:05 Corporate

CureVac

Corporate

CureVac Announces Voting Results of General Meeting

28 May 2024

13:00 Corporate

CureVac

Corporate

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

23 May 2024

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

24 April 2024

13:06 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

13:03 Corporate

CureVac

Corporate

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

13:00 Corporate

CureVac

Corporate

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

18 April 2024

13:00 Corporate

CureVac

Corporate

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

16 April 2024

13:00 Corporate

CureVac

Corporate

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

4 April 2024

13:00 Corporate

CureVac

Corporate

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

5 January 2024

13:00 Corporate

CureVac

Corporate

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

19 December 2023

15:23 Corporate

CureVac

Corporate

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

14 November 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

1 November 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

28 September 2023

13:00 Corporate

CureVac

Corporate

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

12 September 2023

13:00 Corporate

CureVac

Corporate

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

17 August 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

1 August 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

14 July 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Update to the Management Team

13 July 2023

13:00 Corporate

CureVac

Corporate

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

20 June 2023

13:05 Corporate

CureVac

Corporate

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

13:00 Corporate

CureVac

Corporate

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

19 June 2023

17:30 Corporate

CureVac

Corporate

CureVac Announces Voting Results of General Meeting

30 May 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

19 May 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

8 May 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

25 April 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

18 April 2023

13:00 Corporate

CureVac

Corporate

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

Upcoming Events

No Events found